NYSE - Delayed Quote • USD
CONMED Corporation (CNMD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:01 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 8 | 8 | 8 | 8 |
Avg. Estimate | 0.91 | 1.16 | 4.29 | 5.5 |
Low Estimate | 0.88 | 1.12 | 4.26 | 5.28 |
High Estimate | 0.99 | 1.22 | 4.3 | 5.73 |
Year Ago EPS | 0.83 | 0.9 | 3.45 | 4.29 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 8 | 8 | 8 | 8 |
Avg. Estimate | 334.37M | 334.04M | 1.34B | 1.45B |
Low Estimate | 333.4M | 328.5M | 1.33B | 1.43B |
High Estimate | 336.28M | 338.5M | 1.35B | 1.47B |
Year Ago Sales | 306.09M | 304.58M | 1.24B | 1.34B |
Sales Growth (year/est) | 9.20% | 9.70% | 7.70% | 8.20% |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | 0.79 | 0.83 | 1.11 | 0.74 |
EPS Actual | 0.83 | 0.9 | 1.06 | 0.79 |
Difference | 0.04 | 0.07 | -0.05 | 0.05 |
Surprise % | 5.10% | 8.40% | -4.50% | 6.80% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.91 | 1.16 | 4.29 | 5.5 |
7 Days Ago | 0.97 | 1.19 | 4.33 | 5.62 |
30 Days Ago | 0.97 | 1.19 | 4.33 | 5.62 |
60 Days Ago | 0.99 | 1.18 | 4.33 | 5.62 |
90 Days Ago | 1.08 | 1.1 | 4.4 | 5.82 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | 1 | -- | -- |
Up Last 30 Days | -- | 1 | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 8 | 7 | 7 | 7 |
Growth Estimates
CURRENCY IN USD | CNMD | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 9.60% | -- | -- | 6.50% |
Next Qtr. | 28.90% | -- | -- | 12.00% |
Current Year | 24.30% | -- | -- | 5.30% |
Next Year | 28.20% | -- | -- | 13.10% |
Next 5 Years (per annum) | 24.40% | -- | -- | 11.09% |
Past 5 Years (per annum) | 5.52% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | JP Morgan: Overweight to Overweight | 4/25/2024 |
Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 4/25/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 4/25/2024 |
Maintains | Needham: Buy to Buy | 4/25/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 2/1/2024 |
Maintains | JP Morgan: Overweight to Overweight | 2/1/2024 |
Related Tickers
IART Integra LifeSciences Holdings Corporation
28.34
-0.25%
ITGR Integer Holdings Corporation
109.58
-1.41%
NARI Inari Medical, Inc.
38.42
+0.92%
IRTC iRhythm Technologies, Inc.
111.91
+0.58%
PEN Penumbra, Inc.
204.41
-0.53%
CVRX CVRx, Inc.
14.69
+2.08%
EW Edwards Lifesciences Corporation
86.43
-1.80%
TMCI Treace Medical Concepts, Inc.
10.40
+0.97%
LIVN LivaNova PLC
55.53
+0.78%
STE STERIS plc
203.90
+1.17%